finanzen.net

Hat Qimonda ein Chance wieder aufzustehen?

Seite 632 von 632
neuester Beitrag: 11.12.17 16:21
eröffnet am: 23.11.08 09:58 von: arne.r1 Anzahl Beiträge: 15782
neuester Beitrag: 11.12.17 16:21 von: tberg Leser gesamt: 1098120
davon Heute: 1
bewertet mit 33 Sternen

Seite: 1 | ... | 628 | 629 | 630 | 631 |
 

12.01.14 14:37

4681 Postings, 3634 Tage tbergabwarten mr. bean

an der börse ist nichts unmöglich gelle? :-) den spruch meine ich mal von dir gelesen zu haben !
-----------
"Anfangen ist leicht, Durchhalten eine Kunst ."

15.01.14 22:20

1031 Postings, 3669 Tage KernleDa kommt nichts mehr

Das Ding ist tot. Aus basta, nada, Ende, Conergy.  

25.09.14 15:25

233 Postings, 3179 Tage Martin Sp.Zahlungen

Haben die Altaktionäre Chancen von dieser Infineonzahlung etwas abzubekkommen ?.
Wer kann hier darauf eine plausible Antwort geben ?  

17.02.16 20:53

6 Postings, 1710 Tage fwschulzQimonda will Inotera-Verkauf rückgangig machen

und hat schon in der ersten Instanz gewonnen. Da geht es um mindestens 1,2Mrd$(natürlich nur wenn Qimonda gewinnt). Sollte es klappen wird es sicherlich auch was für die Aktionäre übrig bleiben.

Aus dem Quartallsbericht von Micron:
On January 20, 2011, Dr. Michael Jaffé, administrator for Qimonda insolvency proceedings, filed suit against Micron and Micron Semiconductor B.V., our Netherlands subsidiary ("Micron B.V."), in the District Court of Munich, Civil Chamber. The complaint seeks to void under Section 133 of the German Insolvency Act a share purchase agreement between Micron B.V. and Qimonda signed in fall 2008 pursuant to which Micron B.V. purchased substantially all of Qimonda's shares of Inotera Memories, Inc. (the "Inotera Shares"), which represents approximately 55% of our total shares in Inotera as of December 3, 2015, and seeks an order requiring us to re-transfer those shares to the Qimonda estate. The complaint also seeks, among other things, to recover damages for the alleged value of the joint venture relationship with Inotera and to terminate under Sections 103 or 133 of the German Insolvency Code a patent cross-license between us and Qimonda entered into at the same time as the share purchase agreement.

Following a series of hearings with pleadings, arguments, and witnesses on behalf of the Qimonda estate, on March 13, 2014, the Court issued judgments:  (1) ordering Micron B.V. to pay approximately $1 million in respect of certain Inotera shares sold in connection with the original share purchase; (2) ordering Micron B.V. to disclose certain information with respect to any Inotera Shares sold by it to third parties; (3) ordering Micron B.V. to disclose the benefits derived by it from ownership of the Inotera Shares, including in particular, any profits distributed on such shares and all other benefits; (4) denying Qimonda's claims against Micron for any damages relating to the joint venture relationship with Inotera; and (5) determining that Qimonda's obligations under the patent cross-license agreement are canceled. In addition, the Court issued interlocutory judgments ordering, among other things:  (1) that Micron B.V. transfer to the Qimonda estate the Inotera Shares still owned by it and pay to the Qimonda estate compensation in an amount to be specified for any Inotera Shares sold to third parties; and (2) that Micron B.V. pay the Qimonda estate as compensation an amount to be specified for benefits derived by it from ownership of the Inotera Shares. The interlocutory judgments have no immediate, enforceable effect on us, and, accordingly, we expect to be able to continue to operate with full control of the Inotera Shares subject to further developments in the case. We have filed a notice of appeal, and the parties have submitted briefs to the appeals court.

We are unable to predict the outcome of the matter and therefore cannot estimate the range of possible loss. The final resolution of this lawsuit could result in the loss of the Inotera Shares or monetary damages, unspecified damages based on the benefits derived by Micron B.V. from the ownership of the Inotera Shares, and/or the termination of the patent cross-license, which could have a material adverse effect on our business, results of operation, or financial condition.  As of December 3, 2015, the Inotera Shares had a carrying value in equity method investments of $664 million and a market value of $855 million.  

02.09.17 14:38

5 Postings, 2784 Tage estra51Hab immer noch die Papiere

07.09.17 15:56

274 Postings, 3623 Tage Gratulationeestra51

ich auch........  

11.12.17 16:21

4681 Postings, 3634 Tage tbergIch auch ......

-----------
"Anfangen ist leicht, Durchhalten eine Kunst ."

Seite: 1 | ... | 628 | 629 | 630 | 631 |
 
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
MTU Aero Engines AG Em 2017A2G83P
Braas Monier Building Group S.A.BMSA01
Wirecard AG747206
EVOTEC SE566480
Deutsche Bank AG514000
XING (New Work)XNG888
Daimler AG710000
CommerzbankCBK100
BayerBAY001
SteinhoffA14XB9
Microsoft Corp.870747
NEL ASAA0B733
Amazon906866
Apple Inc.865985
BASFBASF11